Edition:
United States

Novavax Inc (NVAX.O)

NVAX.O on Nasdaq

1.35USD
23 Jan 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.35
Open
$1.35
Day's High
$1.39
Day's Low
$1.33
Volume
5,296,356
Avg. Vol
16,181,517
52-wk High
$8.49
52-wk Low
$1.16

Summary

Name Age Since Current Position

James Young

64 2011 Independent Chairman of the Board

Stanley Erck

67 2011 President, Chief Executive Officer, Director

Barclay Phillips

53 2013 Chief Financial Officer, Senior Vice President, Treasurer

Gregory Glenn

62 2016 President, Research and Development

John Herrmann

50 2014 Senior Vice President, General Counsel, Corporate Secretary

Bob Darius

2016 Senior Vice President - Quality Operations

Amy Fix

2016 Senior Vice President - Regulatory Affairs

Louis Fries

2016 Senior Vice President and Chief Medical Officer

John Trizzino

56 2014 Senior Vice President - Commercial Operations

Iksung Cho

2016 Vice President - Biostatistics

Jeffrey Stoddard

2016 Vice President - Medical Affairs

Rajiv Modi

55 2009 Director

Gail Boudreaux

55 2015 Independent Director

Richard Douglas

63 2010 Independent Director

Gary Evans

58 2011 Independent Director

Michael McManus

73 1998 Independent Director

Biographies

Name Description

James Young

Dr. James F. Young, Ph.D., is an Independent Chairman of the Board of Novavax, Inc. since April 2011. He was Former President, Research and Development, MedImmune, Inc. Dr. Young has been Chairman of the Board since April 2011 and a Director of Novavax, Inc. since April 2010. Dr. Young held the position of President, Research and Development, at MedImmune, Inc. from 2000 until 2008 and previously served as Executive Vice President, Research and Development from 1999 to 2000, Senior Vice President from 1995 to 1999, and as Senior Vice President, Research and Development from 1989 to 1995. Dr. Young currently sits on the board of directors of 3-V Biosciences, Inc., a privately-held biopharmaceutical company developing novel antiviral therapeutics, and is the chairman of the board of MicroCoal Technologies Inc., a company developing clean-coal technology.

Stanley Erck

Mr. Stanley C. Erck is the President, Chief Executive Officer, Director of Novavax, Inc., since April 19,2011. From 2000 to 2008, Mr. Erck served as President and Chief Executive Officer of Iomai Corporation, a developer of vaccines and immune system therapies, which was acquired in 2008 by Intercell AG. He also previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now part of Sanofi, and Baxter International. Mr. Erck also serves on the board of directors of BioCryst Pharmaceuticals and MaxCyte, Inc. Mr. Erck received a B.S. in Economics from the University of Illinois and a M.B.A. from the University of Chicago.

Barclay Phillips

Mr. Barclay A. Phillips is Chief Financial Officer, Senior Vice President, Treasurer of Novavax, Inc. Prior to joining the Company, Mr. Phillips served as Senior Vice President and Chief Financial Officer of Micromet, Inc., which was acquired by Amgen in 2012. Previously, he was Managing Director of Vector Fund Management and a Biotechnology Analyst and Director of Venture Investments at Invesco Funds Group, Inc. Mr. Phillips received a B.A. in Economics from the University of Colorado at Boulder.

Gregory Glenn

Dr. Gregory M. Glenn M.D., is President, Research and Development of Novavax, Inc. Prior to joining the Company, Dr. Glenn was the Chief Scientific Officer and founder of Iomai Corporation, which was acquired in 2008 by Intercell AG, an associate in international health at Johns Hopkins University’s School of Public Health and a clinical and basic research scientist at Walter Reed Army Institute of Research. Dr. Glenn received a B.A. in Biology and Chemistry from Whitman College and a M.D. from Oral Roberts University School of Medicine. He also completed the Medical Research Fellowship at the Walter Reed Army Institute of Research.

John Herrmann

Mr. John A. Herrmann, III is the Senior Vice President, General Counsel, Corporate Secretary of the Company. He previously served as the Company’s Vice President, General Counsel and Corporate Secretary from March 2012 to June 2014, and its Executive Director, Legal Affairs and Corporate Secretary from April 2010 to March 2012. Prior to joining the Company, Mr. Herrmann was General Counsel at Ore Pharmaceuticals and Deputy General Counsel at Gene Logic before it became Ore Pharmaceuticals. Mr. Herrmann worked as Senior Counsel for Celera Genomics following his position as Senior Corporate Counsel at Baxter Healthcare in its Renal Division. Mr. Herrmann received a B.A. in political science and history from Brown University and a J.D. from the University of Illinois.

Bob Darius

Mr. Bob Darius is Senior Vice President - Quality Operations of the company. He joins Novavax with over 25 years of experience in Quality Assurance, Quality Control and strategic manufacturing. As VP Quality Operations at GlaxoSmithKline (GSK) Biologicals, he provided oversight of the North American and German Vaccine Manufacturing Operations for over 10 years and most recently transitioned to Head Quality Advocacy Liaison. Mr. Darius also held positions of increasing responsibility at the Food and Drug Administration, Center for Biologics Evaluation and Research, where he was a Senior Reviewer and Inspector, Advisor to the Deputy Center Director, Medicine, on counter-bioterrorism products. He earned a Bachelor of Science degree in Biology from George Mason University and completed graduate work in biotechnology at Johns Hopkins University.

Amy Fix

Ms. Amy B. Fix is Senior Vice President - Regulatory Affairs of the company. She joined Novavax in April 2013 as Vice President, Regulatory Affairs and is responsible for regulatory strategy, regulatory operations, and interactions with international regulatory agencies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency, and a number of other global regulatory agencies, which oversee the development and commercialization of Novavax vaccines. Prior to joining Novavax, Ms. Fix was Senior Director of Global Regulatory Affairs at Emergent Biosolutions after serving in Regulatory Affairs positions of increasing responsibility at a number of pharmaceutical companies, including Human Genome Sciences, Shire, MedImmune and Baxter.

Louis Fries

Dr. Louis F. Fries III Senior Vice President and Chief Medical Officer of the company. He joined Novavax in 2011 with over 22 years of experience in clinical testing and development of human vaccines in academic, small biotech, and major biopharmaceutical environments. Dr. Fries' extensive experience in infectious diseases, including influenza, bacterial and parasitic vaccines, and therapeutic and prophylactic immunoglobulins has lead to over 60 peer-reviewed publications. Prior to Novavax, Dr. Fries served as Director of Clinical Development from 2005 to 2011 of ID Biomedical (later acquired by GSK Biologicals. He has previously served in senior positions at Intellivax, Univax and Nabi and was a faculty member in the Department of International Health, at Johns Hopkins School of Hygiene and Public Health and trained in internal medicine at Johns Hopkins and infectious disease at the National Institutes of Allergy and Infectious Disease.

John Trizzino

Mr. John J. Trizzino is Senior Vice President - Commercial Operations of Novavax, Inc. He previously served as the Company’s Senior Vice President, Business Development from June 2010 to September 2011, and its Senior Vice President, International and Government Alliances from July 2009 to June 2010. Prior to joining the Company, Mr. Trizzino was the CEO of Immunovaccine from September 2011 to September 2013, the VP, Vaccine Franchise at Medimmune, LLC, the Senior Vice President, Business Development at ID Biomedical, and Vice President, Business Development in the Medical Group of Henry Schein, Inc. following his position as Vice President, General Manager of its GIV division. Mr. Trizzino received a B.S. from Long Island University, CW Post and a M.B.A. from New York University.

Iksung Cho

Mr. Iksung Cho is Vice President - Biostatistics of the Company. He joined Novavax in December 2015 as Executive Director, Biostatistics with responsibility for coordinating statistical and statistical programming activities for vaccine candidates in various stages of clinical development. Prior to joining Novavax he was Senior Statistician at PATH, an international nonprofit organization that aims to accelerate innovation across vaccines, drugs, diagnostics, devices and system and service innovations.   Mr. Cho's experience includes positions of increasing responsibility in biostatistics and data management at Aviron, Merck and MedImmune, where he was Vice President of Global Biostatistics. He earned Master's degrees in both statistics and applied mathematics from Virginia Polytechnic and State University and completed graduate studies in mathematics. 

Jeffrey Stoddard

Dr. Jeffrey Stoddard, M.D., is Vice President - Medical Affairs of the Company. Dr. Stoddard joins Novavax with more than 15 years of vaccine research and development experience and leadership roles. He was instrumental in the commercial launch of multiple vaccines and biologics including Synagis®, FluMist®, pandemic flu vaccines, Menveo® and Bexsero®. He was most recently Vice President, Medical Affairs & Medical Professional Services, at Alkermes plc, where he led medical affairs, and health economics and outcomes research. Prior to Alkermes, Dr. Stoddard held positions of increasing responsibility at Novartis Vaccines, Covance and MedImmune. Dr. Stoddard earned his medical degree from the University of Wisconsin Medical School, a Bachelor of Science degree from the University of Wisconsin-Madison, and completed a residency at Johns Hopkins Hospital and a postdoctoral fellowship in the Pew Health Policy program at the University of California, San Francisco.

Rajiv Modi

Dr. Rajiv I. Modi, Ph.D., is Director of Novavax, Inc., since April 1, 2009. He is Managing Director of Cadila Pharmaceuticals, Ltd. (“Cadila”), a company organized in India, since 1995. Dr. Modi was elected to the Board based upon his relationship with the Company’s largest stockholder at the time. As of April 20, 2015, Satellite Overseas (Holdings) Limited, a subsidiary of Cadila, holds approximately 2.8% of the Company’s outstanding Common Stock. Dr. Modi serves as a member of the boards of other Cadila group companies. Dr. Modi received a bachelor’s degree of technology in chemical engineering from the Indian Institute of Technology, a master’s degree in biological engineering from University College, London, and a Ph.D. in biological science from the University of Michigan.

Gail Boudreaux

Ms. Gail Koziara Boudreaux is Independent Director of Novavax, Inc. Ms. Boudreaux most recently served as the Executive Vice President of UnitedHealth Group from May 2008 until February 2015 and was the Chief Executive Officer of UnitedHealthcare from January 2011 to November 2014. Her extensive experience includes more than 30 years of service across a broad spectrum of health care operations. Ms. Boudreaux is currently a director of Zimmer Holdings, Inc. and Xcel Energy Inc. and a trustee of Dartmouth College. Ms. Boudreaux holds a Master of Business Administration degree in finance and health care administration from the Columbia Business School and a bachelor's degree in psychology from Dartmouth College. She has been honored as one of Fortune's 50 Most Powerful Women in American Business for the last six years and was recognized by Modern Healthcare as one of the Top 25 Women in Healthcare.

Richard Douglas

Dr. Richard H. Douglas, Ph.D., is an Independent Director of Novavax, Inc., since 2010. From 1989 to 2011, Dr. Douglas led Genzyme Corporation’s Corporate Development team, and was involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. From 1982 until its merger with Genzyme Corporation in 1989, Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Dr. Douglas was a postdoctoral fellow in Leroy Hood’s laboratory at the California Institute of Technology. Dr. Douglas serves on the University of Michigan Technology Transfer National Advisory Board. Dr. Douglas received a Ph.D. from the University of California, Berkeley in biochemistry and a B.S. in chemistry from the University of Michigan.

Gary Evans

Mr. Gary C. Evans is an Independent Director of Novavax, Inc. He is Chairman of the Board and Chief Executive Officer of Magnum Hunter Resources Corporation, a NYSE Amex listed oil and gas company, since May 2009, and Chairman, President, Chief Executive Officer and Founder of GreenHunter Energy, Inc., a NYSE Amex listed alternative energy company, since 2007. Former Lead Independent Director of Novavax, Inc. from March 2007 until April 2011, and Chairman of the Board of Directors of Novavax, Inc. from April 2005 until March 2007. Mr. Evans was Chairman, President and Chief Executive Officer of Magnum Hunter Resources, Inc., a NYSE listed oil and gas exploration and production company, from 1995 to 2005, and Chairman and Chief Executive Officer of its predecessor, Hunter Resources, Inc., from 1985 to 1995. Mr. Evans is currently an Individual Trustee of TEL Offshore Trust, a publicly listed oil and gas trust and serves on the Board of the Maguire Energy Institute at Southern Methodist University.

Michael McManus

Mr. Michael A. McManus, Jr., J.D. is an Independent Director of Novavax, Inc., since 1998. He has been President and Chief Executive Officer of Misonix, Inc., a medical device company, since October 1998. Mr. McManus served as President, Chief Executive Officer and Director of New York Bancorp Inc. from 1991 through March 1998. He also served as President and Chief Executive Officer of Home Federal Savings Bank, the principal subsidiary of New York Bancorp Inc., from February 1995 through March 1998. From 1990 through November 1991, Mr. McManus was President and Chief Executive Officer of Jamcor Pharmaceuticals Inc. Mr. McManus served as an Assistant to the President of the United States from 1982 to 1985 and held positions with Pfizer Inc. and Revlon Group. Mr. McManus served in the U.S. Army Infantry from 1968 through 1970. Mr. McManus serves as a member of the board of directors of A. Schulman Inc. Mr. McManus is a recipient of the Ellis Island Medal of Honor. Mr. McManus received a B.A. in economics from the University of Notre Dame and a J.D. from the Georgetown University Law Center.

Basic Compensation

Name Fiscal Year Total

James Young

734,500

Stanley Erck

4,851,800

Barclay Phillips

1,352,680

Gregory Glenn

1,872,010

John Herrmann

1,304,060

Bob Darius

--

Amy Fix

--

Louis Fries

--

John Trizzino

1,332,320

Iksung Cho

--

Jeffrey Stoddard

--

Rajiv Modi

--

Gail Boudreaux

271,298

Richard Douglas

317,800

Gary Evans

323,300

Michael McManus

330,800
As Of  30 Dec 2015